ADULT Updated: April 2, 2024

Regimen Reference Order – GYNE – DOXOrubicin

ARIA: GYNE - [DOXOrubicin]

To order this therapy in ARIA, refer to Additional Information below

Planned Course: Every 21 days for 6 to 8 cycles Indication for Use: Endometrial Cancer, Recurrent

CVAD: Preferred (VESICANT INVOLVED)

Proceed with treatment if:

Cycle 1

ANC equal to or greater than 1.5 x $10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

Cycle 2 and Onwards

ANC equal to or greater than $1.2 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$

Contact Physician if parameters not met

Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
	Drug	Dose	CCMB Administration Guideline	
Not Applicable				

Treatment Regimen – GYNE – DOXOrubicin Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline				
Cycles 1 to 5						
prepitant	125 mg	Orally 1 hour pre-chemotherapy				
DLANZapine	2.5 mg	Orally 30 minutes pre-chemotherapy				
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy				
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy				
DOXOrubicin	60 mg/m ²	IV push over 10 minutes				
Cycles 6 to 8						
aprepitant	125 mg	Orally 1 hour pre-chemotherapy				
OLANZapine	2.5 mg	Orally 30 minutes pre-chemotherapy				
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy				
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy				

ADULT GYNE – DOXOrubicin

	dexrazoxane*	10:1 ratio of dexrazoxane to DOXOrubicin	ONLY to be given once patient will receive a total DOXOrubicin dose that will exceed 300 mg/m² IV made up to a final concentration of 3 mg/mL in Lactated Ringer's over 30 minutes immediately prior to the administration of DOXOrubicin *Nursing Alert: dexrazoxane infusion must be complete prior to DOXOrubicin administration		
Ш	DOXOrubicin	60 mg/m ²	IV push over 10 minutes		
	*dexrazoxane dose (mg/m²) is usually dosed at a ratio of dexrazoxane: DOXOrubicin 10:1. Refer to Shared Health Parenteral Drug Monograph for further information				

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Hepatitis B serology

· Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

Cardiac Monitoring

• Left Ventricular Ejection Fraction (LVEF) at baseline and as clinically indicated

All Cycles

• CBC, serum creatinine, urea, electrolytes and liver enzymes as per Physician Orders

Recommended Support Medications					
Drug		Dose	CCMB Administration Guideline		
aprepitant	80 mg	S	Orally once daily on Days 2 and 3		
dexamethasone	8 mg		Orally once daily on Days 2, 3 and 4		
OLANZapine	2.5 m	g	Orally the evening of Day 1 then twice daily on Days 2, 3 and 4. Also use OLANZapine 2.5 to 5 mg AS NEEDED for breakthrough nausea and vomiting (including Days 1 to 4) up to a maximum of 10 mg per day. Contact clinic if nausea/vomiting is not adequately controlled		

DISCHARGE INSTRUCTIONS

- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy
- Instruct patient to continue taking anti-emetic(s) at home



ADULT GYNE – DOXOrubicin

ADDITIONAL INFORMATION

• Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy *Hepatitis B Monitoring for Oncology and Hematology Patients* for ordering and interpreting HBV serology and prescribing antiviral prophylaxis

- DOXOrubicin is cardiotoxic
- dexrazoxane should be added to treatment regimen after patient has received a cumulative DOXOrubicin dose of 300 mg/m² (usually at cycle 6) or cumulative lifetime anthracycline dose is exceeded. dexrazoxane is prescribed to provide cardioprotection from anthracycline-associated toxicity
- Note: For Cycles 6 to 8, an entry called "Physician Reminder Order dexrazoxane if indicated 1 Units Insert
 Miscellaneous once" will appear in the electronic drug order. This prompt is to remind the prescriber to order
 dexrazoxane if indicated
- <u>ARIA ordering</u>: Please note that ARIA regimens/protocols require DOXOrubicin and dexrazoxane to be ordered separately
 - o Support protocol is available for dexrazoxane under dexrazoxane in the "Heart Damage" folder

